{"id":"W4220729116","doi":"10.1158/1538-7445.sabcs21-ot2-11-05","title":"Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable <i>ESR1</i>m who have not experienced disease progression on first-line therapy","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Internal medicine; Metastatic breast cancer; Cancer; Oncology; Breast cancer; Aromatase inhibitor; Aromatase; Estrogen receptor; Fulvestrant; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001277049,0.001460229,0.002158145,0.0003734617,0.0003067489,0.001360275,0.0009172781,0.001258543,0.007452833],"category_scores_gemma":[0.0007263837,0.0006593067,0.001870882,0.0004367393,0.0008767111,0.0008555175,0.0002818472,0.00410055,0.001970269],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008496819,"about_ca_system_score_gemma":0.001213484,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009318254,"about_ca_topic_score_gemma":0.002539427,"domain_scores_codex":[0.999697,0.0001257911,0.00001787909,0.00005504458,0.0000379131,0.00006650417],"domain_scores_gemma":[0.9994796,0.00006316564,0.0000952144,0.00005352155,0.00003973846,0.0002687494],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7968252,0.06950475,0.002452408,0.001218992,0.001908266,0.0002093364,0.0001623054,0.00164299,0.04552771,0.0003528674,0.004251963,0.0759433],"study_design_scores_gemma":[0.5690612,0.4177589,0.005606967,0.00005232886,0.0006552496,0.0002510878,0.00005721607,0.00102367,0.002697221,0.0001587695,0.002642511,0.0000348372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874812,0.00415597,0.0005929035,0.0005214501,0.0002855478,0.00191928,0.002136001,0.0001678445,0.002739842],"genre_scores_gemma":[0.9791998,0.004189822,0.001480711,0.001133614,0.000251062,0.002019027,0.004725572,0.00005335537,0.006947109],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007452833,"threshold_uncertainty_score":0.02493227,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06113314548597167,"score_gpt":0.4015729937799294,"score_spread":0.3404398482939577,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}